| Premedication to Reduce Amivantamab Associated Infusion Related Reactions (NCT05663866) | Janssen Research & Development, LLC | 2023-05-18 |
| A Study of JNJ-77474462 (Bermekimab) in Healthy Chinese Participants (NCT05252520) | Janssen Research & Development, LLC | 2023-05-01 |
| A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI) (NCT05841030) | Janssen Research & Development, LLC | 2023-04-28 |
| A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer (NCT05818683) | Janssen Research & Development, LLC | 2023-04-26 |
| A Study on the Effect of Nipocalimab on Vaccine Responses in Healthy Participants (NCT05827874) | Janssen Research & Development, LLC | 2023-04-12 |
| A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation (NCT05757869) | Janssen Research & Development, LLC | 2023-04-11 |
| A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (NCT05754957) | Janssen Research & Development, LLC | 2023-04-07 |
| A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (NCT05572515) | Janssen Research & Development, LLC | 2023-03-29 |
| A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC) (NCT05714202) | Janssen Research & Development, LLC | 2023-03-23 |
| A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) (NCT05811351) | Janssen Research & Development, LLC | 2023-03-06 |
| A Study of JNJ-64281802 for the Prevention of Dengue Infection (NCT05201794) | Janssen Research & Development, LLC | 2023-02-22 |
| A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (NCT05702034) | Janssen Research & Development, LLC | 2023-02-15 |
| A Study of JNJ-77242113 Following Oral Administration in Healthy Chinese Adult Participants (NCT05703841) | Janssen Research & Development, LLC | 2023-02-14 |
| A Study to Investigate Acute Respiratory Virus Infections in Participants at High Risk for Severe Illness (NCT05661604) | Janssen Research & Development, LLC | 2023-01-19 |
| A Study of Four Different Oral Tablet Formulations of Lazertinib (JNJ-73841937) in Healthy Adult Participants (NCT05742594) | Janssen Research & Development, LLC | 2023-01-03 |
| A Study of Daratumumab (NCT05438043) | Janssen Research & Development, LLC | 2022-12-15 |
| A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer (NCT05488314) | Janssen Research & Development, LLC | 2022-12-13 |
| A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma (NCT05653427) | Janssen Research & Development, LLC | 2022-12-08 |
| A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy (NCT05550532) | Janssen Research & Development, LLC | 2022-12-06 |
| A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma (NCT05564052) | Janssen Research & Development, LLC | 2022-12-06 |
| A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis (NCT05652335) | Janssen Research & Development, LLC | 2022-11-22 |
| A Study of JNJ-80038114 in Participants With Advanced Stage Prostate Cancer (NCT05441501) | Janssen Research & Development, LLC | 2022-11-15 |
| A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma (NCT05552222) | Janssen Research & Development, LLC | 2022-10-25 |
| A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment (NCT05455320) | Janssen Research & Development, LLC | 2022-10-13 |
| A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies (NCT05453903) | Janssen Research & Development, LLC | 2022-10-04 |
| Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (NCT05327114) | Janssen Research & Development, LLC | 2022-09-23 |
| A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (NCT05242484) | Janssen Research & Development, LLC | 2022-09-19 |
| A Single Ascending Dose Study of JNJ-88260237 in Healthy Participants (NCT05541315) | Janssen Research & Development, LLC | 2022-09-14 |
| A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (NCT05528510) | Janssen Research & Development, LLC | 2022-09-13 |
| A Study to Assess Feasibility of Using Clinician-directed and Digital Application Supported Cognitive Behavior Therapy (CBT) in Conjunction With Esketamine in Participants With Treatment-resistant Depression (NCT05268497) | Janssen Research & Development, LLC | 2022-09-01 |
| A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis (NCT05083182) | Janssen Research & Development, LLC | 2022-08-30 |
| A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 4 (NCT05522517) | Janssen Research & Development, LLC | 2022-08-22 |
| A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (NCT05424822) | Janssen Research & Development, LLC | 2022-08-18 |
| A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma (NCT05421663) | Janssen Research & Development, LLC | 2022-08-12 |
| A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer (NCT05388669) | Janssen Research & Development, LLC | 2022-08-05 |
| A Study to Assess the Acceptability of the Darunavir/Cobicistat (DRV/COBI) Fixed-dose Combination (FDC) Tablet in Human Immunodeficiency Virus (HIV)-1 Infected Children (NCT05197075) | Janssen Research & Development, LLC | 2022-08-03 |
| A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer (NCT05379595) | Janssen Research & Development, LLC | 2022-07-29 |
| A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (NCT05242471) | Janssen Research & Development, LLC | 2022-07-22 |
| A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms (NCT05444530) | Janssen Research & Development, LLC | 2022-07-21 |
| A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis (NCT05265273) | Janssen Research & Development, LLC | 2022-07-20 |
| Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis (NCT05272150) | Janssen Research & Development, LLC | 2022-07-13 |
| A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (NCT04919512) | Janssen Research & Development, LLC | 2022-07-07 |
| A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies (NCT05379634) | Janssen Research & Development, LLC | 2022-07-05 |
| A Single and Multiple Ascending Dose Study of JNJ-64457744 (NCT05423106) | Janssen Research & Development, LLC | 2022-07-04 |
| An Efficacy and Safety Study of a Combination of JNJ-73763989, Nucleos(t)Ide Analogs (NA), and a Programmed Cell Death Protein Receptor-1 (PD-1) Inhibitor in Chronic Hepatitis B Participants (NCT05275023) | Janssen Research & Development, LLC | 2022-06-30 |
| A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy (NCT05455684) | Janssen Research & Development, LLC | 2022-06-22 |
| A Study of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis (NCT05357755) | Janssen Research & Development, LLC | 2022-06-13 |
| A Long-term Extension Study of JNJ-77242113 in Participants With Moderate-to-Severe Plaque Psoriasis (NCT05364554) | Janssen Research & Development, LLC | 2022-06-10 |
| A Study of Darunavir in the Presence of Cobicistat When Administered as a Fixed Dose Combination Compared to the Co-administration of the Separate Available Formulations of Darunavir and Cobicistat Under Fed Conditions in Healthy Participants (NCT05378906) | Janssen Research & Development, LLC | 2022-06-07 |
| A Thorough QT Study of Aticaprant (JNJ-67953964) in Healthy Adult Participants (NCT05387759) | Janssen Research & Development, LLC | 2022-05-30 |
| A Study of JNJ-80202135 in Healthy Chinese Adult Participants (NCT05151692) | Janssen Research & Development, LLC | 2022-05-30 |
| A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma (NCT05338775) | Janssen Research & Development, LLC | 2022-05-25 |
| A Study of Seltorexant in Participants With Probable Alzheimer's Disease (NCT05307692) | Janssen Research & Development, LLC | 2022-05-19 |
| Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer (NCT05316155) | Janssen Research & Development, LLC | 2022-04-11 |
| A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (NCT05295927) | Janssen Research & Development, LLC | 2022-03-23 |
| A Study of Ustekinumab Treatment in Children With Crohn's Disease (NCT05242458) | Janssen Research & Development, LLC | 2022-03-21 |
| A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel (NCT05201781) | Janssen Research & Development, LLC | 2022-03-09 |
| A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis (NCT05250973) | Janssen Research & Development, LLC | 2022-03-01 |
| A Study of JNJ-70075200 in Healthy Participants (NCT04782661) | Janssen Research & Development, LLC | 2022-03-01 |
| A Study of JNJ-64281802 in Healthy Adult Participants (NCT05201937) | Janssen Research & Development, LLC | 2022-02-23 |
| A Study of JNJ-42847922 (Seltorexant) in Healthy Participants (NCT05236868) | Janssen Research & Development, LLC | 2022-02-03 |
| A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque Psoriasis (NCT05223868) | Janssen Research & Development, LLC | 2022-02-03 |
| A Study of JNJ-64281802 in Participants With Confirmed Dengue Fever (NCT04906980) | Janssen Research & Development, LLC | 2022-01-24 |
| A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (NCT05197049) | Janssen Research & Development, LLC | 2022-01-19 |
| A Study of 14C JNJ-67953964 in Healthy Adult Male Participants (NCT05197062) | Janssen Research & Development, LLC | 2022-01-14 |
| A Study to Determine the Abuse Potential of Seltorexant Compared to Suvorexant and Zolpidem (NCT05106153) | Janssen Research & Development, LLC | 2021-12-17 |
| A Study in Healthy Adult Participants to Assess the Effects of Ciclosporin Administration on Rilematovir (NCT05155007) | Janssen Research & Development, LLC | 2021-12-10 |
| A Study of Ustekinumab (STELARA) in Chinese Participants With Moderately to Severely Active Crohn's Disease (NCT05029921) | Janssen Research & Development, LLC | 2021-12-10 |
| A Study of JNJ-73763989, JNJ-64300535, and Nucleos(t)Ide Analogs in Virologically Suppressed, Hepatitis B e Antigen (HBeAg)- Negative Participants With Chronic Hepatitis B Virus Infection (NCT05123599) | Janssen Research & Development, LLC | 2021-12-06 |
| A Study to Evaluate the Effect of Hepatic Impairment on Lazertinib (JNJ-73841937) (NCT05112952) | Janssen Research & Development, LLC | 2021-11-30 |
| A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure (NCT04988295) | Janssen Research & Development, LLC | 2021-11-17 |
| A Study of Rilematovir (JNJ-53718678) in Adult Outpatients With Respiratory Syncytial Virus (RSV) Infection (NCT04978337) | Janssen Research & Development, LLC | 2021-11-17 |
| A Study of Guselkumab and Risankizumab in Healthy Participants and Participants With Psoriatic Arthritis (NCT05083078) | Janssen Research & Development, LLC | 2021-11-04 |
| A Study of JNJ-73763989, Pegylated Interferon Alpha-2a and Nucleos(t)Ide Analogs in Participants With Chronic Hepatitis B Virus Infection (NCT05005507) | Janssen Research & Development, LLC | 2021-11-03 |
| A Standard of Care Study of Patients With Major Depressive Disorder Who Have Had an Inadequate Response to a Selective Serotonin Reuptake/Serotonin-Norepinephrine Reuptake Inhibitor Antidepressant (NCT05109195) | Janssen Research & Development, LLC | 2021-10-26 |
| A Study of Pentosan Polysulfate Sodium and the Development of Pigmentary Maculopathy and Pigmentary Retinopathy (NCT05179460) | Janssen Research & Development, LLC | 2021-10-26 |
| A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis (NCT05071664) | Janssen Research & Development, LLC | 2021-10-25 |
| A Study of JNJ-78306358 in Participants With Advanced Stage Solid Tumors (NCT04991740) | Janssen Research & Development, LLC | 2021-10-24 |
| A Study of JNJ-67484703 in Participants With Active Rheumatoid Arthritis (NCT04985812) | Janssen Research & Development, LLC | 2021-10-18 |
| A Long-term Extension Study of Ustekinumab in Pediatric Participants (NCT05092269) | Janssen Research & Development, LLC | 2021-10-18 |
| A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (NCT05083169) | Janssen Research & Development, LLC | 2021-10-14 |
| A Proof-of-concept Study of the Efficacy and Safety of Nipocalimab in Participants With Active Rheumatoid Arthritis (NCT04991753) | Janssen Research & Development, LLC | 2021-10-14 |
| A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (NCT04988308) | Janssen Research & Development, LLC | 2021-10-12 |
| Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent (NCT04936308) | Janssen Research & Development, LLC | 2021-09-28 |
| A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants (NCT05022849) | Janssen Research & Development, LLC | 2021-09-28 |
| A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma (NCT05050097) | Janssen Research & Development, LLC | 2021-09-22 |
| A Study of JNJ-73763989 in Adult Participants With Renal Impairment (NCT04963738) | Janssen Research & Development, LLC | 2021-09-22 |
| A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS) (NCT04968912) | Janssen Research & Development, LLC | 2021-09-21 |
| A Study of Rilematovir in Infants and Children and Subsequently in Neonates Hospitalized With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus (RSV) (NCT04583280) | Janssen Research & Development, LLC | 2021-09-06 |
| A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents With Major Depressive Disorder Who Have an Inadequate Response to Selective Serotonin Reuptake Inhibitor (SSRI) and Psychotherapy (NCT04951609) | Janssen Research & Development, LLC | 2021-09-02 |
| A Study of Bermekimab for the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis (NCT04990440) | Janssen Research & Development, LLC | 2021-09-02 |
| A Study of Nipocalimab With Co-administration of Etanercept or Hydroxychloroquine in Healthy Participants (NCT04973566) | Janssen Research & Development, LLC | 2021-08-31 |
| A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease (NCT04929210) | Janssen Research & Development, LLC | 2021-08-30 |
| A Study of Guselkumab (TREMFYA) in Chinese Participants With Moderate to Severe Plaque Psoriasis (NCT04914429) | Janssen Research & Development, LLC | 2021-08-25 |
| A Study of Nipocalimab in Adult Participants With Active Systemic Lupus Erythematosus (NCT04882878) | Janssen Research & Development, LLC | 2021-08-20 |
| A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy (NCT04923893) | Janssen Research & Development, LLC | 2021-08-19 |
| A Study to Evaluate the Effect of Hepatic Impairment on JNJ-42847922 in Adult Participants (NCT04960124) | Janssen Research & Development, LLC | 2021-08-05 |
| A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 3 (NCT04985955) | Janssen Research & Development, LLC | 2021-07-30 |
| A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis (NCT04951622) | Janssen Research & Development, LLC | 2021-07-15 |
| A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer (NCT04898634) | Janssen Research & Development, LLC | 2021-07-13 |